Myasthenia Gravis Foundation of America meets the 20 Standards for Charity Accountability.
-
Year, State Incorporated
1952, NY
-
-
-
Stated Purpose
"to find a cure for Myasthenia Gravis and closely related disorders, to improve treatment options and to provide information and support to people with Myasthenia Gravis through research, education, community programs and advocacy."
Myasthenia Gravis Foundation of America (MGFA) works to provide those with Myasthenia Gravis (MG) and their loved ones with information, education and support. The organization engages in patient advocacy activities, provides resources for support groups, and funds research projects through post-doctoral fellowships and student fellowships. Research funds focus on clinical trials and general research into the cause and cure of MG. MGFA hosts a database, MG Patient Registry, that collects voluntary patient information for the purpose of research, treatment, advocacy, and awareness. In 2019, the organization hosted over 300 attendees at its annual conference, held nearly 30 MG walks to fund research, and helped establish the MG Rare Disease Network, which is focused on enhancing therapeutic development for MG. Some ($287,201 or 17%) of MGFA's program activities are carried out in conjunction with fundraising appeals.
For the year ended December 31, 2019, Myasthenia Gravis Foundation of America's program expenses were:
Research |
$636,901 |
Community and patient services |
$539,490 |
Awareness and advocacy |
$356,965 |
National conference |
$189,274 |
Total Program Expenses: |
$1,722,630 |
*Current compensation information not available for Ms. Masterson.
Note: Samantha Masterson became Chief Executive Officer on February 24, 2020. In 2019, the previous Chief Executive Officer, Nancy Law, received $157,612 in compensation.
Method(s) Used:
Direct mail appeals, Internet, Invitations to fund raising events, Planned giving arrangements
MGFA incurred joint costs of $467,082 for informational materials and activities that included fundraising materials. Of those costs $287,201 was allocated to program expenses and $179,881 was allocated to fundraising expenses.
Fundraising costs were 15% of related contributions. (Related contributions, which totaled $2,137,928, are donations received as a result of fundraising activities.)
This organization is tax-exempt under section 501(c) (3) of the Internal Revenue Code.It is eligible to receive contributions deductible as charitable donations for federal income tax purposes.
The following information is based on Myasthenia Gravis Foundation of America's audited financial statements for the year ended December 31, 2019.
Source of Funds |
Investment return, net |
$1,264,288 |
MG Walk |
$870,557 |
Sponsorships |
$365,050 |
Individuals |
$339,353 |
Fundraising events |
$239,557 |
Foundations |
$158,146 |
Revenue from research studies |
$106,360 |
Corporations |
$74,464 |
Charitable organizations |
$45,000 |
Bequests |
$44,067 |
Other income |
$36,569 |
Conference fees |
$34,417 |
Public agencies |
$1,734 |
Merchandise sales |
$90 |
Total Income |
$3,579,652 |
- Programs: 73%
- Administrative: 14%
- Fundraising: 13%
Total Income |
$3,579,652 |
Program expenses |
$1,722,630 |
Fundraising expenses |
$319,175 |
Administrative expenses |
$336,136 |
Other expenses |
$0 |
Total expenses: |
$2,377,941 |
Income in Excess of Expenses |
$1,201,711 |
Beginning Net Assets |
$7,338,929 |
Other Changes In Net Assets |
$0 |
Ending Net Assets |
$8,540,640 |
Total Liabilities |
$971,735 |
Total Assets |
$9,512,375 |